Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
The gyrA and gyrB genes of Chlamydia pneumoniae TW-183 were cloned, and their proteins were purified by use of a fusion system with a maltose-binding protein. The 50% inhibitory concentrations of garenoxacin, sparfloxacin, moxifloxacin, gatifloxacin, and levofloxacin were 10.1, 47.5, 39.6, 64.2, and 156.9 microg/ml, respectively, and the MICs against C. pneumoniae TW-183 were 0.008, 0.016, 0.063, 0.125, and 0.25 microg/ml, respectively.
Ameyama
Satoshi
S
Research Laboratories, Toyama Chemical Co, Ltd, Toyama 930-8508, Japan. SATOSHI_AMEYAMA@toyama-chemical.co.jp
Shinmura
Yuko
Y
Takahata
Masahiro
M
D000890:Anti-Infective Agents / Q000494:pharmacology; D001372:Aza Compounds; D016993:Chlamydophila pneumoniae / Q000187:drug effects* / Q000201:enzymology*; D027081:DNA Gyrase / Q000235:genetics; D024841:Fluoroquinolones / Q000494:pharmacology; D000077734:Gatifloxacin; D005798:Genes, Bacterial; D007211:Indoles / Q000494:pharmacology*; D064704:Levofloxacin; D008969:Molecular Sequence Data; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000494:pharmacology; D011804:Quinolines; D015363:Quinolones / Q000494:pharmacology*; D059005:Topoisomerase II Inhibitors
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D007211:Indoles; D011804:Quinolines; D015363:Quinolones; D059005:Topoisomerase II Inhibitors; D064704:Levofloxacin; D015242:Ofloxacin; D027081:DNA Gyrase; D000077734:Gatifloxacin; C061363:sparfloxacin; D000077266:Moxifloxacin; C419689:garenoxacin